Posts by: Joana Carvalho, PhD

Joana Carvalho, PhD

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

May 8, 2020May 8, 2020

Yervoy Can Benefit Certain mCRPC Patients with Few Mutations in Tumors, Trial Finds

News

Men with metastatic castration-resistant prostate cancer (mCRPC) showing evidence of active immune responses in their tumors live longer without disease progression after being treated with Yervoy (ipilimumab), a Phase ... Read more

April 17, 2020April 17, 2020

Cancer Vaccine Plus Opdivo Showing Promise in Advanced Prostate Cancer Trial

News

A combination of Vaccitech’s experimental vaccine VTP-800 and Opdivo (nivolumab) appears to be a safe and potentially effective treatment for men with metastatic castration resistant prostate cancer (mCRPC), according to early data ... Read more

February 24, 2020February 24, 2020

Cabometyx-Tecentriq Combo Leads to Lasting Response in Men with Advanced PC, Phase 1b Trial Data Shows

News

The combination of Cabometyx (cabozantinib) and Tecentriq (atezolizumab) is safe and shows clinically meaningful activity, leading to lasting responses in men with metastatic castration-resistant prostate cancer (mCRPC), a Phase 1b ... Read more

October 24, 2019October 25, 2019

Prostate Cancer Patients May Safely Skip Radiation Therapy After Surgery, Phase 3 Trial Shows

News

Men with prostate cancer who undergo surgery have similar long-term outcomes whether they receive radiation therapy shortly after the surgery or only when signs of disease recurrence appear, suggesting ... Read more

October 17, 2019

Erleada-ADT Combo Increases Survival of mCSPC Patients Without Affecting Quality of Life, Phase 3 Trial Shows

News

Adding Erleada (apalutamide) to standard androgen deprivation therapy (ADT) increases the survival and delays disease progression in men with metastatic castration-sensitive prostate cancer (mCSPC) — and does so without ... Read more

October 7, 2019

Jevtana Delays Disease Progression, Prolongs Survival in Men with mCRPC, Phase 4 Trial Shows

News

The chemotherapy agent Jevtana (cabazitaxel) is better than a second course of androgen receptor inhibitors at delaying disease progression and prolonging survival among men with metastatic castration-resistant prostate cancer ... Read more

September 16, 2019

PSMA PET-CT Offers Better Detection Rates in Recurrent PC, Study Says

News

The imaging agent 68Ga-PSMA-11 has better detection rates than 18F-fluciclovine in men with recurrent prostate cancer who have already had radical surgery to remove the prostate and whose levels ... Read more

September 5, 2019

Collaborators Work to Develop New Sequencing Methods to Manage Cancers

News

The nonprofit organization Genome Canada, the pharmaceutical company Thermo Fisher Scientific and the Ontario Institute for Cancer Research (OICR) are collaborating to develop new targeted next generation sequencing (NGS) ... Read more

August 28, 2019

Telix Enters Collaboration with DKFZ Researchers to Develop Image-Guided Surgery

News

Telix Pharmaceuticals has established a collaboration agreement with a team of researchers from the German Cancer Research Center (Deutsches Krebsforschungszentrum, or DKFZ) to develop an innovative image-guided surgery for ... Read more

August 26, 2019

Request for Xtandi to Treat Metastatic Hormone-sensitive Prostate Cancer Before FDA

News

The U.S. Food and Drug Administration (FDA) has agreed to review Astellas Pharma and Pfizer‘s application for Xtandi (enzalutamide), requesting its approved use be expanded to include men whose metastatic ... Read more

Pin It on Pinterest